Haematologica · 2003
Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Konopleva Marina, Cheng Su-Chun, Cortes Jorge E, Hayes Kimberly J, Pierce Sherry A, Andreeff Michael, Giles Francis J, O'Brien Susan, Kantarjian Hagop M, Estey Elihu H
Аннотация
BACKGROUND AND OBJECTIVES: We investigated whether cytogenetic findings (CG) on day 21 (D21) of the first course of chemotherapy predicted subsequent outcome in patients who presented with CG abnormalities.
DESIGN AND METHODS: D21 CG analysis was performed in 197 patients.
RESULTS: Nineteen percent of the patients had exclusively abnormal metaphases (AA), 31% had only normal metaphases (NN), 39% had normal and abnormal metaphases (AN), and 11% had insufficient metaphases (0/0) on D21. A complete response was achieved in 79% of patients with NN, 60% with AN, 27% of those with AA, and 32% of those with 0/0.
INTERPRETATIONS AND CONCLUSIONS: Disease-free survival in CR was longest in patients who had > or =1 normal metaphase on D21, with this finding being independent of D21 marrow and initial CG results. D21 CG can be used in therapeutic decision-making.
DESIGN AND METHODS: D21 CG analysis was performed in 197 patients.
RESULTS: Nineteen percent of the patients had exclusively abnormal metaphases (AA), 31% had only normal metaphases (NN), 39% had normal and abnormal metaphases (AN), and 11% had insufficient metaphases (0/0) on D21. A complete response was achieved in 79% of patients with NN, 60% with AN, 27% of those with AA, and 32% of those with 0/0.
INTERPRETATIONS AND CONCLUSIONS: Disease-free survival in CR was longest in patients who had > or =1 normal metaphase on D21, with this finding being independent of D21 marrow and initial CG results. D21 CG can be used in therapeutic decision-making.